Axia Pharmaceutical Recalls Alprostadil Injectable Due to Sterility Concerns
Axia Pharmaceutical is recalling Alprostadil injectable vials due to a lack of assurance of sterility. The affected product is distributed in the U.S., Puerto Rico, Barbados, and the Dominican Republic.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls with potential for adverse health consequences (such as sterility issues in injectables) are categorized as Severe (Score 4), as they are not explicitly Class I but involve significant risk.
Plain-English summary
Axia Pharmaceutical, doing business as Fusion IV Pharmaceuticals, Inc., is recalling Alprostadil (prostaglandin E1) 150 MCG/ML Injectable, For Intracavernosal Use. The product is a 2.5 mL multi-dose vial intended for prescription use only. The recall is being conducted due to a lack of assurance of sterility.
The affected product is identified by Lot # 12042019+53331 with an expiration date of 1/17/2020. The NDC number is 71283-0538-2. The product was distributed nationwide in the United States, as well as in Puerto Rico, Barbados, and the Dominican Republic.
Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or the recalling firm for further instructions. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Alprostadil (prostaglandin E1)150 MCG/ML Injectable, For Intracavernosal Use, Freeze, 2.5 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0538-2
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 12042019+53331
- Exp 1/17/2020
Distribution
Part of a larger recall action
This product is one of 63 recalled by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 63 products in this recall →Related recalls
Same manufacturer · Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
See all →- Severe
- SevereAxia Pharmaceutical Recalls Selenium Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- Severe
- SevereAxia Pharmaceutical Recalls Hydroxyprogesterone Caproate Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- SevereAxia Pharmaceutical Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29